613 related articles for article (PubMed ID: 25633683)
1. Effect of empagliflozin monotherapy on postprandial glucose and 24-hour glucose variability in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, 4-week study.
Nishimura R; Tanaka Y; Koiwai K; Inoue K; Hach T; Salsali A; Lund SS; Broedl UC
Cardiovasc Diabetol; 2015 Jan; 14():11. PubMed ID: 25633683
[TBL] [Abstract][Full Text] [Related]
2. Pharmacokinetic and Pharmacodynamic Properties and Tolerability of Single- and multiple-dose Once-daily Empagliflozin, a Sodium Glucose Cotransporter 2 Inhibitor, in Chinese Patients With Type 2 Diabetes Mellitus.
Zhao X; Cui Y; Zhao S; Lang B; Broedl UC; Salsali A; Pinnetti S; Macha S
Clin Ther; 2015 Jul; 37(7):1493-502. PubMed ID: 26101175
[TBL] [Abstract][Full Text] [Related]
3. Effect of Empagliflozin on Free Fatty Acids and Ketone Bodies in Japanese Patients with Type 2 Diabetes Mellitus: A Randomized Controlled Trial.
Nishimura R; Tanaka Y; Koiwai K; Ishida K; Salsali A; Kaspers S; Kohler S; Lund SS
Adv Ther; 2019 Oct; 36(10):2769-2782. PubMed ID: 31444706
[TBL] [Abstract][Full Text] [Related]
4. Glucose Exposure and Variability with Empagliflozin as Adjunct to Insulin in Patients with Type 1 Diabetes: Continuous Glucose Monitoring Data from a 4-Week, Randomized, Placebo-Controlled Trial (EASE-1).
Famulla S; Pieber TR; Eilbracht J; Neubacher D; Soleymanlou N; Woerle HJ; Broedl UC; Kaspers S
Diabetes Technol Ther; 2017 Jan; 19(1):49-60. PubMed ID: 27929674
[TBL] [Abstract][Full Text] [Related]
5. Improved glucose control with weight loss, lower insulin doses, and no increased hypoglycemia with empagliflozin added to titrated multiple daily injections of insulin in obese inadequately controlled type 2 diabetes.
Rosenstock J; Jelaska A; Frappin G; Salsali A; Kim G; Woerle HJ; Broedl UC;
Diabetes Care; 2014 Jul; 37(7):1815-23. PubMed ID: 24929430
[TBL] [Abstract][Full Text] [Related]
6. Effects of Dapagliflozin on 24-Hour Glycemic Control in Patients with Type 2 Diabetes: A Randomized Controlled Trial.
Henry RR; Strange P; Zhou R; Pettus J; Shi L; Zhuplatov SB; Mansfield T; Klein D; Katz A
Diabetes Technol Ther; 2018 Nov; 20(11):715-724. PubMed ID: 30222367
[TBL] [Abstract][Full Text] [Related]
7. Safety, tolerability and effects on cardiometabolic risk factors of empagliflozin monotherapy in drug-naïve patients with type 2 diabetes: a double-blind extension of a Phase III randomized controlled trial.
Roden M; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2015 Dec; 14():154. PubMed ID: 26701110
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of empagliflozin in Japanese patients with type 2 diabetes mellitus: A sub-analysis by body mass index and age of pooled data from three clinical trials.
Shiba T; Ishii S; Okamura T; Mitsuyoshi R; Pfarr E; Koiwai K
Diabetes Res Clin Pract; 2017 Sep; 131():169-178. PubMed ID: 28753486
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of empagliflozin monotherapy for 52 weeks in Japanese patients with type 2 diabetes: a randomized, double-blind, parallel-group study.
Kadowaki T; Haneda M; Inagaki N; Terauchi Y; Taniguchi A; Koiwai K; Rattunde H; Woerle HJ; Broedl UC
Adv Ther; 2015 Apr; 32(4):306-18. PubMed ID: 25845768
[TBL] [Abstract][Full Text] [Related]
10. Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus.
Kovacs CS; Seshiah V; Merker L; Christiansen AV; Roux F; Salsali A; Kim G; Stella P; Woerle HJ; Broedl UC;
Clin Ther; 2015 Aug; 37(8):1773-88.e1. PubMed ID: 26138864
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of monotherapy with the novel sodium/glucose cotransporter-2 inhibitor tofogliflozin in Japanese patients with type 2 diabetes mellitus: a combined Phase 2 and 3 randomized, placebo-controlled, double-blind, parallel-group comparative study.
Kaku K; Watada H; Iwamoto Y; Utsunomiya K; Terauchi Y; Tobe K; Tanizawa Y; Araki E; Ueda M; Suganami H; Watanabe D;
Cardiovasc Diabetol; 2014 Mar; 13():65. PubMed ID: 24678906
[TBL] [Abstract][Full Text] [Related]
12. Rationale, design and baseline characteristics of a 4-year (208-week) phase III trial of empagliflozin, an SGLT2 inhibitor, versus glimepiride as add-on to metformin in patients with type 2 diabetes mellitus with insufficient glycemic control.
Ridderstråle M; Svaerd R; Zeller C; Kim G; Woerle HJ; Broedl UC;
Cardiovasc Diabetol; 2013 Sep; 12():129. PubMed ID: 24007456
[TBL] [Abstract][Full Text] [Related]
13. Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Häring HU; Merker L; Seewaldt-Becker E; Weimer M; Meinicke T; Broedl UC; Woerle HJ;
Diabetes Care; 2014 Jun; 37(6):1650-9. PubMed ID: 24722494
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of tofogliflozin in Japanese patients with type 2 diabetes mellitus with inadequate glycaemic control on insulin therapy (J-STEP/INS): Results of a 16-week randomized, double-blind, placebo-controlled multicentre trial.
Terauchi Y; Tamura M; Senda M; Gunji R; Kaku K
Diabetes Obes Metab; 2017 Oct; 19(10):1397-1407. PubMed ID: 28371205
[TBL] [Abstract][Full Text] [Related]
15. Empagliflozin improves glycaemic and weight control as add-on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24-week, randomized, placebo-controlled trial.
Kovacs CS; Seshiah V; Swallow R; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Diabetes Obes Metab; 2014 Feb; 16(2):147-58. PubMed ID: 23906415
[TBL] [Abstract][Full Text] [Related]
16. Empagliflozin monotherapy in Japanese patients with type 2 diabetes mellitus: a randomized, 12-week, double-blind, placebo-controlled, phase II trial.
Kadowaki T; Haneda M; Inagaki N; Terauchi Y; Taniguchi A; Koiwai K; Rattunde H; Woerle HJ; Broedl UC
Adv Ther; 2014 Jun; 31(6):621-38. PubMed ID: 24958326
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of teneligliptin added to glimepiride in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled study with an open-label, long-term extension.
Kadowaki T; Kondo K
Diabetes Obes Metab; 2014 May; 16(5):418-25. PubMed ID: 24205974
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial.
Kaku K; Inoue S; Matsuoka O; Kiyosue A; Azuma H; Hayashi N; Tokudome T; Langkilde AM; Parikh S
Diabetes Obes Metab; 2013 May; 15(5):432-40. PubMed ID: 23194084
[TBL] [Abstract][Full Text] [Related]
19. Comparison Of Efficacy And Safety Profile Of Empagliflozin As A Combination Therapy In Obese Type 2 Diabetic Patients.
Babar M; Hussain M; Ahmad M; Akhtar L
J Ayub Med Coll Abbottabad; 2021; 33(2):188-191. PubMed ID: 34137526
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial.
Barnett AH; Mithal A; Manassie J; Jones R; Rattunde H; Woerle HJ; Broedl UC;
Lancet Diabetes Endocrinol; 2014 May; 2(5):369-84. PubMed ID: 24795251
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
